Q4 2025 Exelixis Inc Earnings Call Transcript
Key Points
- Exelixis Inc (EXEL) reported strong financial performance with a 17% growth in US cabo franchise product revenues, reaching approximately $2.12 billion for the full year 2025.
- The company maintained its leadership position with CABOMETYX as the leading TKI for renal cell carcinoma (RCC) and neuroendocrine tumors in the oral second-line-plus segment.
- Exelixis Inc (EXEL) is advancing zanzalintinib as its next oncology franchise opportunity, with seven ongoing and planned pivotal trials.
- The company has a robust pipeline with potential first-in-class and best-in-class molecules, demonstrating differentiating activity based on extensive preclinical testing.
- Exelixis Inc (EXEL) has a strong balance sheet with approximately $1.66 billion in cash and marketable securities, supporting its pipeline priorities and share repurchase program.
- Gross to net deductions for the cabozantinib franchise decreased in the fourth quarter of 2025, primarily due to lower PHS and 340B volume.
- The company faces variability in 340B purchasing behavior, which could impact gross to net figures due to the heavily discounted segment.
- Exelixis Inc (EXEL) anticipates a 2% discount on all Medicare Part D sales in 2026, affecting gross to net estimates.
- Operating expenses increased sequentially in the fourth quarter of 2025, driven by higher manufacturing costs, NDA filing fees, and personnel expenses.
- The company is dependent on successful regulatory approval and commercialization of zanzalintinib to sustain growth, with potential challenges in the competitive oncology market.
Good day, ladies and gentlemen, and welcome to the Exelixis fourth quarter and fiscal year 2025 financial results conference call. My name is Tawanda, and I'll be your operator for today. As a reminder, this call is being recorded for replay purposes.
I would now like to turn the call over to your host for today, Mr. Andrew Peters, Senior Vice President of Strategy and Investor Relations. Please proceed.
Thank you, Tawanda, and thank you all for joining us for the Exelixis fourth quarter and fiscal year 2025 financial results conference call. Joining me on today's caller are Mike Morrissey, our President and CEO; Chris Senner, our Chief Financial Officer; Dana Aftab, our Executive Vice President, Research and Development; and PJ Haley, our Executive Vice President, Commercial, who will review our progress for the fourth quarter and fiscal year 2025 ended December 31, 2025.
During the call today, we will refer to financial measures not calculated according to generally accepted
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
